Canopy Growth: A Critical Juncture Amid Acquisition and Persistent Losses

Canopy Growth reports flat revenue and persistent losses, but narrows EBITDA loss. Shareholders overwhelmingly approve MTL Cannabis acquisition to boost medical segment.

Canopy Growth Corporation finds itself at a potentially pivotal moment. The cannabis producer is navigating the final stages of a significant acquisition while its latest earnings report underscores a prolonged struggle toward profitability. With revenue stagnation, sustained losses, and a share price languishing 99% below its peak, the company’s strategic moves are under intense scrutiny.

Financial Performance: Stalled Revenue and Mounting Annual Losses

For the third quarter of fiscal year 2026, ending December 31, 2025, Canopy Growth reported net revenue of 74.5 million Canadian dollars, showing little change from the same period the previous year. A closer look reveals a mixed picture within different business segments. Canadian recreational cannabis sales saw an 8% increase, while the medical segment posted a more robust 15% gain, fueled by a growing patient base and larger order volumes. The company’s Storz & Bickel device brand benefited from seasonal demand, and its VEAZY vaporizer became the best-selling device in the firm’s history.

However, margin pressures persist. The consolidated gross margin contracted to 29% from 32%, and the cannabis-specific gross margin fell to 25%. International cannabis revenue, a segment expected to deliver higher margins, declined sharply by 31%. On a positive note, the adjusted EBITDA loss showed improvement for the third consecutive quarter, narrowing by 17% to 3 million Canadian dollars.

The annual figures paint a starker picture. Total losses for the trailing twelve months reached 326.6 million Canadian dollars, with an operating cash burn of 78.7 million. A notable bright spot was the reduction in loss per share, which fell significantly from 1.11 to 0.18 Canadian dollars, indicating that cost-control measures are having an effect.

Strategic Acquisition: Overwhelming Approval for MTL Cannabis

In a move to bolster its medical cannabis platform, Canopy Growth is nearing the completion of its acquisition of MTL Cannabis Corp. The transaction received resounding approval from MTL shareholders at a special meeting on February 17. An overwhelming 99.97% of votes cast were in favor, with approximately 89% of eligible shareholders participating. The deal is expected to close within the current quarter.

Canopy Growth cites strategic expansion in Canada’s medical cannabis sector as the primary rationale. MTL brings substantial financial contributions to the table, including net revenue of 84 million Canadian dollars for the twelve-month period ending September 30, 2025, a gross margin of 51% before fair value adjustments, and operating cash flow of 11 million Canadian dollars. Furthermore, Canopy Growth anticipates realizing annual cost synergies of approximately 10 million Canadian dollars through integration, achievable within 18 months.

Cost Discipline and a Challenging Market Backdrop

The company has made progress on its cost-reduction initiatives, achieving annualized savings of 29 million Canadian dollars since March 2025. When adjusted for special effects from acquisitions and divestitures, administrative expenses decreased by 12% year-over-year. Management has set a target for positive adjusted EBITDA by fiscal year 2027.

Canopy Growth’s share price trajectory reflects its tumultuous journey. From a market capitalization of approximately 14 billion US dollars five years ago, its value has eroded to less than 500 million US dollars today. External regulatory uncertainty, particularly in the United States, adds to the challenges. The potential reclassification of cannabis from Schedule I to Schedule III remains pending and, in any case, would not equate to federal legalization.

As of December 31, 2025, the company reported liquid assets of 371 million Canadian dollars and a net cash position of 146 million Canadian dollars, providing it with sufficient runway to fund the integration of MTL. Whether this acquisition will mark the long-awaited turning point for Canopy Growth should become clearer with the release of fourth-quarter results.